tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses

Story Highlights
Cardiol Therapeutics Reports Q2 2025 Financial Results Amid Rising Losses

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Cardiol Therapeutics ( (TSE:CRDL) ) has issued an update.

Cardiol Therapeutics Inc. released its financial results for the three and six months ended June 30, 2025, showing a decrease in cash and cash equivalents from $30.6 million at the end of 2024 to $18.2 million. The company reported a net loss of $8.35 million for the three months ended June 30, 2025, compared to a loss of $6.59 million in the same period of 2024. The financial results reflect ongoing investments in research and development, with operating expenses remaining substantial. This financial update indicates the company’s continued focus on advancing its clinical programs, although it faces challenges in managing its financial resources.

The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.

Spark’s Take on TSE:CRDL Stock

According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Underperform.

Cardiol Therapeutics faces substantial financial challenges, primarily driven by ongoing losses and negative cash flow. The stock’s technical indicators suggest mixed momentum, and its valuation is constrained by a negative P/E ratio. However, promising clinical developments and strategic advancements in heart disease treatments provide some positive outlook, though these are not sufficient to offset the financial and technical concerns.

To see Spark’s full report on TSE:CRDL stock, click here.

More about Cardiol Therapeutics

Cardiol Therapeutics Inc. is a pharmaceutical company based in Oakville, Ontario, Canada, specializing in the development of innovative therapies for inflammatory heart diseases. The company focuses on producing cannabinoid-based treatments aimed at addressing heart failure and other cardiovascular conditions.

Average Trading Volume: 112,471

Technical Sentiment Signal: Sell

Current Market Cap: C$127.3M

For an in-depth examination of CRDL stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1